Merck & Co (MRK)

Moderna shares surged 177% after its melanoma vaccine, developed with Merck, outperformed an established therapy in a late-stage trial, triggering a massive short squeeze.

Breaking news: Moderna isn't just a "pandemic stock" after all.

The biotech could be on the verge of setting a new standard of care for skin cancer.

What Happened? Shares of global pharmaceutical company Merck (NYSE:MRK) jumped 11.3% in the afternoon session after the company and its partner Moderna annou...

Most stocks rose Wednesday, but a few big tech names told a different story. Here's what split the market again.

Pfizer Inc (NYSE:PFE) shares are trading higher Wednesday, moving in sympathy with mRNA cancer vaccine-related companies after Merck & Co Inc (NYSE:MRK) and Moderna Inc (NASDAQ:MRNA) announced that their combination therapy of intismeran autogene and Keytruda showed positive recurrence-free survival results in melanoma patients.

The treatment combines an mRNA shot with Merck's Keytruda.

The company's HIV franchise is stronger than ever, and it's adding a stable of oncology drugs.

They have businesses built to handle the toughest environments.

This top dividend ETF is still a reliable long-term income investment.